Drugmaker Group Sets Lobbying Record
- PhRMA spent almost $10 million in first three months of 2018
- Group sought to stop legislation to help generic companies
Trump vs. Big Pharma: Can He Bring Drug Prices Down?
This article is for subscribers only.
The drug industry set several quarterly records for lobbying spending in the first three months of 2018 as it faced pressure from President Donald Trump’s administration and lawmakers on drug pricing, generic medicines and trade.
The Pharmaceutical Research and Manufacturers of America spent $9.96 million on federal lobbying, according to disclosures filed Friday with the government. The trade group increased its spending by nearly $2 million from the same period in 2017, when it also set a quarterly record.